Deriving reference values and utilities for the QoL-AGHDA in adult GHD

European Journal of Health Economics

Volumn 12, Issue 3, 2011, Pages 243-252

  Busschbach, J J V ^a   Wolffenbuttel, B H R ^b   Annemans, L ^c,d   Meerding, W J ^e   Koltowska Haggstrom M ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e PFIZER INC   (United States)

Author keywords

deficiency; Growth hormone ; Quality of life; Quality adjusted life years; Questionnaires; Reference values

Indexed keywords

ADULT; ARTICLE; BELGIUM; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GROWTH HORMONE DEFICIENCY; HEALTH ECONOMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE ASSESSMENT FOR GROWTH HORMONE DEFICIENCY IN ADULT; QUALITY OF LIFE INDEX; QUESTIONNAIRE; REFERENCE VALUE; REGRESSION ANALYSIS; SCORING SYSTEM; VALIDITY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BELGIUM; FEMALE; GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REFERENCE VALUES; SEX FACTORS; YOUNG ADULT;

EID: 79958064112     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0241-7     Document Type: Article

References (32)

1. LJ Woodhouse A Mukherjee SM Shalet S Ezzat 2006 The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults Endocr. Rev. 27 287 317 16543384 10.1210/er.2004-0022 1:CAS:528:DC%2BD28XlsFamsLs%3D
2. College voor Zorgverzekeringen. Pakketbeheer in de praktijk. Report 245. CVZ. http://www.cvz.nl/resources/rpt0612%20pakketbeheer-tcm28-22507.pdf (2006). Accessed 1 May 2009
3. Cleemput, I., Van Wilder, P., Vrijens, F., Huybrechts, M., Ramaekers, D.: Richtlijnen voor farmaco-economisch onderzoek in België. KCE Reports 78A. Federaal Kenniscentrum voor de gezondheidszorg 10/04/2008. http://www.kce.fgov. be/index-nl.aspx?SGREF=5264&CREF=11004 (2008). Accessed 1 May 2009
4. Ministerie Van Sociale Zaken, Volksgezondheid en Leefmilieu. Koninklijk besluit van 21 december 2001 tot vastelling van de procedures, termijnen en voorwaarden inzake de tegemoetkoming van de verplichte verzekering voor geneeskundige verzorging en uitkeringen in de kosten van farmaceutische specialiteiten. Belgisch Staatsblad, 29.12.2001 Ed 3. www.ejustice.just.fgov.be/ cgi/welcome.pl (2001). Accessed 1 May 2009
5. Bansback, N., Brazier, J., Chilcott, J., Kaltenthaler, E., Lloyd-Jones, M., Paisley, S., Walters, S.: Clinical and cost effectiveness of recombinant human growth hormone (Somatropin) in adults. Report prepared on behalf of the national institute for clinical excellence (NICE), 10 April 2002. School of Health and Related Research (ScHARR), University of Sheffield. Available from: www.nice.org.uk (2002). Accessed 1 May 2009
6. Kołtowska-Häggström, M.: Quality of life in adult patients with growth hormone deficiency: bridging the gap between clinical evaluation and health economic assessment. PhD-Thesis of the Uppsala University (Sweden), Medicinska vetenskapsområdet, Faculty of Pharmacy, Department of Pharmacy. http://publications.uu.se/theses (2008). Accessed 1 May 2009
7. Brooks, R., Rabin, R., De Charro, F.: The Measurement and Valuation of Health Status Using Eq-5d: A European Perspective. Kluwer Academic, London (2003)
8. EA Stolk JJV Busschbach 2003 Validity and feasibility of the use of condition-specific outcome measures in economic evaluation Qual. Life Res. 12 363 371 12797709 10.1023/A:1023453405252 (Pubitemid 36609881)
9. M Kołtowska-Häggström B Jonsson D Isacson K Bingefors 2007 Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA) Value Health 10 73 81 17261118 10.1111/j.1524-4733.2006.00146.x (Pubitemid 46164755)
10. M Kołtowska-Häggström P Kind JP Monson B Jonsson 2008 Growth hormone (GH) replacement in hypopituitary adults with GH deficiency evaluated by a utility-weighted quality of life index: a precursor to cost-utility analysis Clin. Endocrinol. 68 122 129 10.1111/j.1365-2265.2007. 03010.x
11. EA Stolk G van Donselaar WB Brouwer JJ Busschbach 2004 Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall Pharmacoeconomics 22 1097 1107 15612829 10.2165/00019053-200422170-00001 (Pubitemid 39665341)
12. Raad voor de Volksgezondheid en Zorg. Zinnige en duurzame zorg. Zoetermeer; RvZ. http://www.rvz.net/data/download/advies-Zinnige-zorg.pdf (2006). Accessed 1 May 2009
13. SM Hunt SP McKenna 1992 The QLDS: a scale for the measurement of quality of life in depression Health Policy 22 307 319 10122730 10.1016/0168-8510(92) 90004-U 1:STN:280:DyaK3s7gtVamug%3D%3D
14. SP McKenna LC Doward J Alonso T Kohlmann M Niero L Prieto L Wíren 1999 The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency Qual. Life Res. 8 373 383 10472170 10.1023/A:1008987922774 1:STN:280:DyaK1MvgtFeqsg%3D%3D (Pubitemid 29369642)
15. L Wirén D Whalley SP McKenna L Wilhelmsen 2000 Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis Clin. Endocrinol. 52 143 152 10.1046/j.1365-2265. 2000.00899.x (Pubitemid 30108259)
16. M Koltowska-Haggstrom AF Mattsson JP Monson P Kind X Badia FF Casanueva J Busschbach HP Koppeschaar G Johannsson 2006 Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur. J. Endocrinol. 155 109 119 16793956 10.1530/eje.1.02176 (Pubitemid 44109071)
17. National Institute for Health and Clinical Excellence (NICE).: Human Growth Homone (somatropin) in adults with growth hormone deficiency (TA 64). http://guidance.nice.org.uk/TA64/Guidance/Recommendation (2003). Accessed Jan 2010
18. Szende, A., Oppe, M., Devlin, N.: EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Springer, Dordrecht (2007)
19. LM Lamers J McDonnell PF Stalmeier PF Krabbe JJ Busschbach 2006 The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies Health Econ. 15 1121 1132 16786549 10.1002/hec.1124 1:STN:280:DC%2BD28rns1ahsA%3D%3D (Pubitemid 44596379)
20. LP Gutiérrez M Kołtowska-Häggström PJ Jönsson AF Mattsson D Svensson B Westberg A Luger 2008 Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database) Pharmacoepidemiol. Drug Saf. 17 90 102 17957812 10.1002/pds.1510 (Pubitemid 351187389)
21. JJV Busschbach J McDonnell ML Essink-Bot BA Van Hout 1999 Estimating parametric relations between health description and health valuation with an application to the EuroQol instrument J. Health Econ. 18 551 571 10621364 10.1016/S0167-6296(99)00008-9 1:STN:280:DyaK1Mvlsl2isA%3D%3D (Pubitemid 29408616)
22. F Orfila M Ferrer R Lamarca, et al. 2006 Gender differences in health-related quality of life among the elderly: the role of objective functional capacity and chronic conditions Soc. Sci. Med. 63 9 2367 2380 16884840 10.1016/j.socscimed.2006.06.017 (Pubitemid 44374824)
23. K Burström M Johannesson F Diderichsen 2001 Swedish population health-related quality of life results using the EQ-5D Qual. Life Res. 10 621 635 11822795 10.1023/A:1013171831202 (Pubitemid 34056332)
24. M Koopmanschap 2002 Coping with type II diabetes: the patient's perspective Diabetologia 45 S18 S22 12136407 1:STN:280:DC%2BD38zoslemsQ%3D%3D
25. A Siderowf B Ravina HA Glick 2002 Preferencebased quality-of-life in patients with Parkinson's disease Neurology 59 103 108 12105315 (Pubitemid 34742802)
26. JL Bosch MG Hunink 2000 Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication Qual. Life Res. 9 591 601 11236850 10.1023/A:1008929129537 1:STN:280: DC%2BD3M3jtl2ktQ%3D%3D (Pubitemid 32146988)
27. BM Craig JJ Busschbach JA Salomon 2009 Modeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methods Med. Care 47 634 641 19433996 10.1097/MLR.0b013e31819432ba
28. L Van Roijen A Beckers A Stevenaert JJV Busschbach W Van Eijk FFH Rutten 1997 The burden of hypopituitarism in adults after pituitary surgery Endocrinol. Metab. 4 Suppl. B 139 142 (Pubitemid 27479850)
29. C Cook F Heath RL Thompson 2000 A meta-analysis of response rates in web- or internet-based surveys Educ. Psychol. Meas. 60 821 836 10.1177/ 00131640021970934
30. P Kind P Dolan C Gudex A Williams 1998 Variations in population health status: results from a United Kingdom national questionnaire survey BMJ 316 736 741 9529408 1:STN:280:DyaK1c7ptVajtw%3D%3D (Pubitemid 28121072)
31. A Boonen D Van der Heijde R Landewé A Van Tubergen H Mielants M Dougados S Van der Linden 2007 How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann. Rheum. Dis. 66 771 777 17213254 10.1136/ard.2006.060384 (Pubitemid 46846696)
32. F Xie S Li N Luo N Lo S Yeo K Yang K Fong J Thumboo 2007 Comparison of the EuroQol and short form 6D in Singapore multiethnic asian knee osteoarthritis patients scheduled for total knee replacement Arthritis Rheum. 57 1043 1049 17665466 10.1002/art.22883 (Pubitemid 47237332)